Insider buying last 90 days
$498Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 10 | Larry L Wood President, CEO | Purchase | $498K |
From Form 4 filings, dated to when each was filed.
NASDAQ: PRCT
PROCEPT BioRobotics (PRCT) Stock Analysis & Forecast
Oct 12 close
$19.57+1.17 (+6.4%)
Gekko Brief
AI summaryOct 12 closePROCEPT BioRobotics this week drew attention from analyst activity and ongoing legal scrutiny. Barclays initiated coverage with an Overweight rating and a $30 price target, then upgraded the stock to "strong-buy," citing confidence in the surgical robotics company despite a broader consensus of "hold" among other firms. The company also confirmed it will report third-quarter 2026 results on 4 November, and separately disclosed a Form 4 insider filing. Meanwhile, a securities lawsuit filed 1 October alleging deceptive discounting practices tied to excess handpiece inventory continues to draw coverage, alongside a shareholder investigation announcement from Johnson Fistel.
PRCT closed at $19.57, up 6.4%, though it remains below both its 50-day average of $19.88 and its 200-day average of $24.25, with the 50-day sitting below the 200-day. The GekkoIndex reads 55.9, placing it in the Neutral zone. Gekko Fair Value stands at $29.34, putting the current price 33.3% below that level.
Over the next 20 trading days, the main event is the earnings report, now set for 3 November, which falls inside that window and follows a quarter where EPS beat by a narrow margin and the stock reacted 5.2%. Smart money shows one open-market insider purchase valued at $498,315 over the last 90 days. Seasonality data shows the next 20 trading days have averaged a 6.8% return over 5 years, rising in 3 of them.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
PROCEPT BioRobotics price vs fair value
Close $19.57200-day averageGekko Fair Value $29.34
PROCEPT BioRobotics quick facts
- Market cap
- $1.11B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.94
- Revenue, TTM
- $337.3M
- Profit margin
- -32.5%
- Dividend yield
- —
- Beta
- 0.92
- Volume
- 2.04M avg 1.40M
- 1-year return
- −43.8%
- Typical daily move
- ±5%
- Typical 20-day move
- ±10.5%
- 50-day average
- $19.88
- 200-day average
- $24.25
- Next earnings
- Nov 3
- Shares outstanding
- 56.92M
PROCEPT BioRobotics swing-trade checklist
PROCEPT BioRobotics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $19.57 is below the 50-day ($19.88) and 200-day ($24.25) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
55.9, Neutral
Reading 55.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
33.3% below
Price is 33.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.8% on average
From this point in the calendar, the next 20 trading days averaged +6.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
PROCEPT BioRobotics stock chart and price history
PROCEPT BioRobotics closed at $19.57 on Oct 12, 2026, −43.8% over the past year, inside a 52-week range of $16.67 to $38.11.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.0%
- 3 months
- +1.3%
- 6 months
- −16.6%
- 1 year
- −43.8%
The full PRCT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PRCT in Gekko
Follow PROCEPT BioRobotics through every session
Put PRCT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PRCT in GekkoFree for 7 days. No credit card required.
About PROCEPT BioRobotics
PROCEPT BioRobotics makes surgical robots used in urology. Its main product, the AquaBeam Robotic System, is an image-guided device built for minimally invasive procedures, and it supports Aquablation therapy, a treatment the company developed to ease lower urinary tract symptoms in men with benign prostatic hyperplasia.
The system is placed with hospitals and surgical centers that treat this condition, giving them a robotic option for performing the procedure rather than relying on conventional surgical methods. By the end of 2021 the company had 130 of these systems installed worldwide, with 78 of them operating in the United States, pointing to a customer base split between domestic and international medical facilities.
PROCEPT BioRobotics was established in 2007 and runs its operations from Redwood City, California. Its shares trade on the NASDAQ under the ticker PRCT.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- procept-biorobotics.com
PROCEPT BioRobotics GekkoIndex: the smart money zone
PROCEPT BioRobotics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.9, in the Neutral zone, down 8.6 points over five sessions.
55.9Neutral
Down 8.6 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 50 | +1.7% | +0.7% | ||
| Accumulation | 319 | −0.5% | −1.0% | ||
| Neutral (current zone) | 290 | −0.6% | −3.3% | ||
| Distribution | 21 | −0.3% | +0.3% | ||
| Selling | 2 | Too few readings yet | |||
Average PRCT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PRCT price, zone by zone.Track PRCT in Gekko
Is PROCEPT BioRobotics stock overvalued? Gekko Fair Value
PROCEPT BioRobotics trades 33.3% below Gekko Fair Value of $29.34, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what PROCEPT BioRobotics shares are worth, recalculated every trading day.
$29.34
Gekko Fair Value, Oct 10, 2026
33.3% Undervalued
At the end of Aug 2026 the price was 35.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PRCT in Gekko
PROCEPT BioRobotics insider and Congress trading
Insiders filed 1 open-market purchase in PROCEPT BioRobotics worth $498K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PRCT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PRCT, plotted on the chart in Gekko.Open PRCT in Gekko
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold PRCT.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
PROCEPT BioRobotics earnings: next date and track record
PROCEPT BioRobotics reports on Nov 3, 2026 (22 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
22 days away
- EPS estimate
- −$0.39
- Revenue estimate
- $100.7M
5 of 8reports beat the EPS estimate
±13.1%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- PROCEPT BioRobotics reported Q2 2026 results showing solid top-line growth driven by continued HYDROS momentum but with a procedure shortfall concentrated in legacy AQUABEAM accounts. Total revenue was $94.5M, up 19% year-over-year; U.S. procedures exceeded 13,100, up ~21% YoY, though below management expectations due to AQUABEAM account softness. HYDROS placements and utilization were strong: 65 HYDROS placements in the quarter (14 replacements) with average ASP for new U.S. systems around $495k. Gross margin was 66% (benefited by a $2.9M tariff recovery). Management is investing in commercial initiatives including launch teams, patient activation/DTC pilots (18 markets), and increased funding for the WATER IV trial; operating expenses rose to $89.8M. Management remains confident in HYDROS, is accelerating upgrades from AQUABEAM to HYDROS, and expects the replacement cycle to continue into 2027. They reiterated full-year targets (with adjustments to procedure assumptions) while increasing targeted commercial spend and maintaining a pathway to be EBITDA positive exiting Q4. Q&A largely focused on drivers of procedure softness, the replacement strategy, launch-team impact, DTC pilot metrics, and margin and guidance assumptions.
- Guidance
- Full-year system revenue guidance implied by commentary: $210M–$220M (greenfield systems); total revenue guidance range: ~$390M–$410M. Handpiece/consumable revenue implied ~$200M–$215M with a target 1:1 handpiece-to-procedure ratio for the full year. International revenue guide: ~$50M–$51M. Management expects roughly ~40 replacement systems for the full year (midpoint assumption). Gross margin guide for the full year: ~55%. They expect to be EBITDA positive exiting Q4 2026. Procedure guidance was lowered (management noted midpoint is ~7,000 procedures lower than prior expectation) and the guide assumes limited improvement at the low end; high end assumes improvement from launch-team scale and replacements. Long-range plan (LRP) remains “in the ballpark” per management, to be updated on normal cadence.
- Risks flagged
- Primary risks/caveats cited: unexpected and concentrated softness in legacy AQUABEAM accounts driving procedure shortfall; uncertainty about the pace and drivers of AQUABEAM declines; competition (e.g., growth in PAE) noted though management downplayed its impact; potential variability in margins (standard costs and inventory production variability); need to successfully scale launch teams and patient activation to restore/utilize procedure volumes; increased OpEx for patient activation may pressure near-term profitability if benefits do not materialize as expected. There was also a mention of tariff recovery effects and their one-time impact on margins.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.47 est −$0.46 | $94.50M est $92.77M | +5.2% |
| Apr 29, 2026 | −$0.56 est −$0.56 | $83.13M est $80.52M | +4.4% |
| Feb 25, 2026 | −$0.53 est −$0.32 | $76.38M est $93.77M | −13.3% |
| Nov 4, 2025 | −$0.38 est −$0.41 | $83.33M est $93.70M | −8.4% |
| Aug 6, 2025 | −$0.35 est −$0.41 | $79.18M est $84.35M | −17.7% |
| Apr 24, 2025 | −$0.45 est −$0.49 | $69.16M est $65.44M | −5.8% |
| Oct 28, 2024 | −$0.40 est −$0.49 | $58.37M est $66.77M | +40.6% |
| Aug 1, 2024 | −$0.50 est −$0.52 | $53.35M est $50.16M | −9.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
PROCEPT BioRobotics stock forecast and analyst price targets
Analysts’ average 12-month price target for PROCEPT BioRobotics is $22.42, +14.6% from the last close, from 12 firms rating the stock in the last 90 days.
$22.42consensus 12-month target, +14.6% from the last close
Now $19.57Avg $22.42
Low $19High $30
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Leerink Partners | $20 | +2.2% |
| Oct 6 | Barclays | $30 | +53.3% |
| Aug 31 | BTIG | — | — |
| Aug 8 | William Blair | — | — |
| Aug 5 | Bank of America Securities | — | — |
−3.3%average 20-day move after past Neutral readings
+6.8%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
PROCEPT BioRobotics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, PROCEPT BioRobotics averaged +6.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 3 of 5 |
| Next 10 trading days | −1.6% | 3 of 5 |
| Next 15 trading days | +5.7% | 4 of 5 |
| Next 20 trading days | +6.8% | 3 of 5 |
| Next 30 trading days | +5.8% | 3 of 5 |
For scale, PRCT’s typical 20-trading-day move in either direction is about 10.5%.
PROCEPT BioRobotics market cap and key statistics
PROCEPT BioRobotics’s market cap is $1.11B and revenue of $337.3M over the last twelve months.
Valuation
- Market cap
- $1.11B
- EPS, TTM
- −$1.94
- Gekko Fair Value
- $29.34
Trading
- Volume
- 2.04M
- Avg volume, 20 days
- 1.40M
- 52-week high
- $38.11
- 52-week low
- $16.67
- Shares outstanding
- 56.92M
Financials
- Revenue, TTM
- $337.3M
- Profit margin
- -32.5%
- Return on equity
- -30.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.92
- Typical daily move
- ±5%
- Typical 20-day move
- ±10.5%
PROCEPT BioRobotics stock news this week
Coverage of PROCEPT BioRobotics this week reads neutral: 2 positive, 3 neutral and 2 negative headlines.
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026GlobeNewsWire, Oct 12
- Form 4 Procept Biorobotics Corp For: 12 October By Investing.comInvesting.com UK, Oct 12
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT)Supply Chain Digital, Oct 10
- PROCEPT BioRobotics (NASDAQ:PRCT) Upgraded at BarclaysMarketBeat, Oct 9
- Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Targetmarketscreener.com, Oct 7
- Procept BioRobotics Corp Share Price - PRCT, RNS News, Articles, Quotes, & Charts (NASDAQ:PRCT)Proactive financial news, Oct 7
PROCEPT BioRobotics peers
PROCEPT BioRobotics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
PROCEPT BioRobotics stock FAQ
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.11B at the Oct 12, 2026 close of $19.57, with 56.92M shares outstanding.
What is the PROCEPT BioRobotics stock forecast?
The consensus analyst 12-month price target for PROCEPT BioRobotics is $22.42, +14.6% from the last close. Of the 12 firms that rated the stock in the last 90 days, 4 rate it a buy, 7 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is PROCEPT BioRobotics stock overvalued or undervalued?
On Gekko’s estimate PROCEPT BioRobotics is undervalued: the Oct 12, 2026 close of $19.57 is 33.3% below Gekko Fair Value of $29.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does PROCEPT BioRobotics report earnings next?
PROCEPT BioRobotics is expected to report on Nov 3, 2026 (22 days away). Analysts expect earnings of −$0.39 per share on revenue of $100.7M. PROCEPT BioRobotics beat the earnings estimate in 5 of its last 8 reports, moving 13.1% on average across the report.
What is PROCEPT BioRobotics’s 52-week high and low?
PROCEPT BioRobotics’s 52-week high is $38.11 and its 52-week low is $16.67; it closed at $19.57 on Oct 12, 2026, −43.8% over the past year. Over the last five years the shares peaked at $103.81 on Nov 11, 2024.
Is PROCEPT BioRobotics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See PROCEPT BioRobotics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.